Metabolic dysfunction-associated steatotic liver disease management in Saudi Arabia: A modified Delphi-based adaptation of international standards
The reclassification of nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) marks a significant shift in understanding liver disease, particularly in Saudi Arabia, where metabolic disorders are highly prevalent. This study aimed to develop expert consensus recommendations for early detection, specialist referral, and management of MASLD/metabolic dysfunction-associated steatohepatitis (MASH) in Saudi Arabia. A modified Delphi process was used to establish consensus among an expert panel of 15 multidisciplinary specialists, including hepatologists, endocrinologists, gastroenterologists, and primary care physicians. The panel addressed six key areas: terminology and epidemiology, screening, risk categories, hepatocellular carcinoma surveillance, first-line treatment, and advanced therapeutic options. A literature review spanning January 2011 to May 2024 informed evidence-based recommendations, assessed using the Grading of Recommendations, Assessment, Development, and Evaluation criteria. The consensus established screening criteria for high-risk groups, emphasizing noninvasive tests (NITs) such as Fibrosis-4 (FIB-4), enhanced liver fibrosis (ELF) score, and magnetic resonance elastography (MRE). Risk stratification thresholds were defined: FIB-4 ≥2.67, liver stiffness measurement (LSM) >12 kPa, and MRE >5.0 kPa indicate advanced fibrosis requiring specialist referral. Treatment recommendations emphasized a multidisciplinary approach, incorporating lifestyle modifications, pharmacotherapy (including glucagon-like peptide-1 receptor agonists [GLP-1 RA], sodium-glucose cotransporter-2 [SGLT2] inhibitors, and pioglitazone), and surgical interventions when appropriate. Bariatric surgery was recommended for eligible patients with noncirrhotic MASLD. This consensus provides evidence-based guidance for MASLD/MASH management in Saudi Arabia, highlighting early detection through NITs, risk-stratified care pathways, and multidisciplinary treatment strategies essential for improving patient outcomes in the region.
Authors
- Saleh A. Alqahtani (ORCID: https://orcid.org/0000-0003-2017-3526)
- Assim A. Alfadda (ORCID: https://orcid.org/0000-0002-4792-5188)
- Mona Ismail (ORCID: https://orcid.org/0000-0001-6371-3997)
- Faisal Abaalkhail
- Ali Alshehri (ORCID: https://orcid.org/0009-0007-2647-6719)
- Mohammad AlEissa
- Saud Alsifri
- Faisal M. Sanai (ORCID: https://orcid.org/0000-0002-3830-9236)
- Majid A. Almadi (ORCID: https://orcid.org/0000-0001-9917-2758)
- Adnan Alzanbagi
- Ahmed Al‐Jedai (ORCID: https://orcid.org/0000-0002-4730-9086)
- Khalid Alswat (ORCID: https://orcid.org/0000-0002-3521-8523)
- Hamdan S. Alghamdi (ORCID: https://orcid.org/0000-0002-8247-3367)
- Waleed Al Hamoudi
- Turki Alzahrani
Institutions
- Riyadh Armed Forces Hospital (SA)
- Alfaisal University (SA)
- King Saud bin Abdulaziz University for Health Sciences (SA)
- Cornell University (US)
- Montreal General Hospital (CA)
- Saudi Aramco Medical Services Organization (SA)
- King Faisal Specialist Hospital & Research Centre (SA)
- King Saud Medical City (SA)
- King Fahd Hospital of the University (SA)
- King Fahd Medical City (SA)
- King Saud University (SA)
- King Abdulaziz Medical City (SA)
- King Abdullah International Medical Research Center (SA)
- Armed Forces Hospital (SA)
- King Khalid University Hospital (SA)
- King Abdullah Medical City (SA)
- Weill Cornell Medicine (US)
- National Guard Health Affairs (SA)
- McGill University (CA)
- Imam Abdulrahman Bin Faisal University (SA)
Publication Details
- Journal
- Saudi Journal of Gastroenterology
- Published
- 2025-09-01
- DOI
- https://doi.org/10.4103/sjg.sjg_199_25
- Citations
- 3
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.06